8-KEarnings & ResultsExhibits & Filings

THERMO FISHER SCIENTIFIC INC. 8-K Report, Financial Results (Apr 6, 2020)

Filed April 6, 2020For Securities:TMO

Summary

This 8-K filing from Thermo Fisher Scientific Inc. (TMO), dated April 6, 2020, primarily serves to furnish a press release detailing the company's financial results for the fiscal quarter ended March 28, 2020. The press release, attached as an exhibit, provides investors with key financial and operational updates. While specific financial figures are not detailed within the 8-K itself, this filing indicates that the company is providing its most recent performance data to the public. Investors should note that the information provided in this filing is subject to cautionary statements regarding forward-looking statements, particularly concerning the ongoing impact of the COVID-19 pandemic, expected revenue growth, and strategic initiatives. The company highlights that actual results could differ materially due to various risks, including the pandemic's duration and severity, technological changes, economic conditions, and potential challenges with acquisitions, such as the pending acquisition of QIAGEN N.V. This filing is crucial for understanding the company's disclosed performance and its outlook in the context of a rapidly evolving global environment.

Key Highlights

  • 1Thermo Fisher Scientific issued a press release on April 6, 2020, reporting on its fiscal quarter ended March 28, 2020.
  • 2The press release is attached as Exhibit 99.1 to the 8-K filing.
  • 3The filing includes standard cautionary statements regarding forward-looking statements.
  • 4Key risks and uncertainties are disclosed, including the impact of the COVID-19 pandemic on expected revenue growth.
  • 5The company references its previous filings (10-K and an earlier 8-K) for a comprehensive list of risk factors.
  • 6The pending acquisition of QIAGEN N.V. is mentioned, along with the risk that expected benefits may not materialize.
  • 7The information furnished in Item 2.02 is not deemed 'filed' for purposes of Section 18 of the Exchange Act.

Frequently Asked Questions

The main purpose of this 8-K filing is to formally announce and furnish Thermo Fisher Scientific's press release containing its financial and operational results for the fiscal quarter ended March 28, 2020.

The detailed financial results are contained within the press release issued on April 6, 2020, which is attached as Exhibit 99.1 to this Form 8-K. Investors should refer to that exhibit for specific financial data.

The company highlights risks and uncertainties related to the duration and severity of the COVID-19 pandemic, the need for product development and adaptation to technological change, economic conditions, customer spending, and government funding. Specific mention is made of potential challenges in realizing expected benefits from the pending acquisition of QIAGEN N.V.

No, the information contained in Item 2.02 of this Form 8-K, including the press release, is furnished and not deemed 'filed' for purposes of Section 18 of the Securities Exchange Act of 1934. Therefore, it is not subject to the liabilities of that section, unless expressly incorporated by reference into another filing.